Compugen (CGEN) Receivables - Net (2009 - 2026)

Compugen (CGEN) posted quarterly Receivables - Net of $5.0 million for Q2 2024, down 91.8% on a QoQ basis from $61.0 million in Q4 2023.

Analysis

Compugen (CGEN) Receivables - Net (2009 - 2026) Analysis & Trends

Compugen has reported Receivables - Net for 11 years, with the latest figure at $5.0 million in Q2 2024.

Receivables - Net for Q2 2024 came in at $5.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2024 was $5.0 million (changed N/A YoY), and the FY2023 annual result was $61.0 million, changed N/A from the prior year.
Receivables - Net declined to $5.0 million in Q2 2024, from $61.0 million in the prior quarter.
Over five years, Receivables - Net peaked at $61.0 million in Q4 2023 and troughed at $2.0 million in Q4 2020.
A 4-year average of $18.5 million and a median of $5.5 million in 2021 frame the typical range for Receivables - Net.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Compugen	242.44 Mn	156.82 Mn	-92,000.00

Historic Data

Download Data